WINDTREE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.49 USD | +4.42% |
|
+9.51% | -65.31% |
| 04-16 | Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04-11 | North American Morning Briefing : Stock Futures -2- | DJ |
Presenter SpeechMatthew Duffy (Analysts)Good afternoon, everybody. Thank you very much for com...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Companyâs portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.49
USD
Average target price
18
USD
Spread / Average Target
+300.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -65.31% | 2.29M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- WINT Stock
- News Windtree Therapeutics, Inc.
- Transcript : Windtree Therapeutics, Inc. - Special Call
